Expression of cAMP-dependent protein kinase isoforms in the human prostate: Functional significance and relation to PDE4

Urology

Volumn 76, Issue 2, 2010, Pages 515.e8-515.e14

  Waldkirch, Eginhard ^a   Ückert, Stefan ^a   Sigl, Katja ^a   Langnaese, Kristina ^a   Richter, Karin ^a   Stief, Christian G ^a   Kuczyk, Markus A ^a   Hedlund, Petter ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA ACTIN; CYCLIC AMP DEPENDENT PROTEIN KINASE; FORSKOLIN; NITROPRUSSIDE SODIUM; NORADRENALIN; PHOSPHODIESTERASE IV; ROLIPRAM; TADALAFIL;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; PHASE TRANSITION; PRIORITY JOURNAL; PROSTATE; PROTEIN EXPRESSION; PROTEIN FUNCTION; SMOOTH MUSCLE; WESTERN BLOTTING;

EID: 77955715186     PISSN: 00904295     EISSN: 15279995     Source Type: Journal    
DOI: 10.1016/j.urology.2010.04.035     Document Type: Article

References (29)

1. M.B. Siroky Lower urinary tract symptoms: shifting our focus from the prostate to the bladder J Urol 172 2004 1237 1238
2. C.R. Chapple, and C.G. Roehrborn A shifted paradigm for the further understanding, evaluation, and treatment of lower urinary tract symptoms in men: focus on the bladder Eur Urol 49 2006 651 659
3. C.G. Roehrborn Current medical therapies for men with lower urinary tract symptoms and benign prostatic hyperplasia: achievements and limitations Rev Urol 10 2008 14 25
4. W. Bloch, T. Klotz, and C. Loch Distribution of nitric oxide synthase implies a regulation of circulation, smooth muscle tone, and secretory function in the human prostate by nitric oxide Prostate 33 1997 1 8
5. P. Hedlund, P. Ekstrom, and B. Larsson Heme oxygenase and NO-synthase in the human prostaterelation to adrenergic, cholinergic and peptide-containing nerves J Auton Nerv Syst 63 1997 115 126
6. S. ckert, M. Oelke, and C.G. Stief Immunohistochemical distribution of cAMP- and cGMP-phosphodiesterase (PDE) isoenzymes in the human prostate Eur Urol 49 2006 740 745
7. E. Waldkirch, S. ckert, and K. Langnse Immunohistochemical distribution of cyclic GMP-dependent protein kinase-one in human prostate tissue Eur Urol 52 2007 495 502
8. K.T. McVary, W. Monnig, and J.L. Camps Jr. Sildenafil citrate improves erectile function and urinary symptoms in men with erectile dysfunction and lower urinary tract symptoms associated with benign prostatic hyperplasia: a randomized, double-blind trial J Urol 177 2007 1071 1077
9. K.T. McVary, C.G. Roehrborn, and J.C. Kaminetsky Tadalafil relieves lower urinary tract symptoms secondary to benign prostatic hyperplasia J Urol 177 2007 1401 1407
10. C.G. Stief, H. Porst, and D. Neuser A randomized, placebo-controlled study to assess the efficacy of twice-daily vardenafil in the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia Eur Urol 53 2008 1236 1244
11. C. Guler, E. Tuzel, E. Dogantekin, and G. Kiziltepe Does sildenafil affect uroflowmetry values in men with lower urinary tract symptoms suggestive of benign prostatic enlargement? Urol Int 80 2008 181 185
12. E.O. Guven, M.D. Balbay, K. Mete, and E.C. Serefoglu Uroflowmetric assessment of acute effects of sildenafil on the voiding of men with erectile dysfunction and symptomatic benign prostatic hyperplasia Int Urol Nephrol 41 2009 287 292
13. S. ckert, A. Kthe, and U. Jonas Characterization and functional relevance of cyclic nucleotide phosphodiesterase isoenzymes of the human prostate J Urol 166 2001 2484 2490
14. S. ckert, M. Sormes, and G.T. Kedia Effects of phosphodiesterase inhibitors on tension induced by norepinephrine and accumulation of cyclic nucleotides in isolated human prostatic tissue Urology 71 2008 526 530
15. J.A. Carvajal, A.M. Germain, J.P. Huidobro-Toro, and C.P. Weiner Molecular mechanism of cGMP-mediated smooth muscle relaxation J Cell Physiol 184 2000 409 420
16. W.F. Jackson Rp diastereomeric analogs of cAMP inhibit both cAMP- and cGMP-induced dilation of hamster mesenteric small arteries Pharmacologist 52 1996 226 234
17. K.E. Andersson Pharmacology of the lower urinary tract: basis for current and future treatment of urinary incontinence Pharmacol Rev 56 2004 581 631
18. K.E. Andersson, S. ckert, C.G. Stief, and P. Hedlund Phosphodiesterases (PDEs) and PDE inhibitors for treatment of LUTS Neurourol Urodyn 26 2007 928 933
19. H. Porst The rationale for prostaglandin E1 in erectile failure: a survey of worldwide experience J Urol 155 1996 802 815
20. M.E. Cvijic, T. Kita, and W. Shih Extracellular catalytic subunit activity of the cAMP-dependent protein kinase in prostate cancer Clin Cancer Res 6 2000 2309 2317
21. A.K. Kvissel, H. Ramberg, and T. Eide Androgen dependent regulation of protein kinase A subunits in prostate cancer cells Cell Signal 19 2007 401 409
22. C. Sparwasser, P. Drescher, and J.A. Will Smooth muscle tone regulation in rabbit cavernosal and spongiosal tissue by cyclic AMP- and cyclic GMP-dependent mechanisms J Urol 152 1994 2159 2163
23. C.G. Stief, S. ckert, and A.J. Becker Effects of sildenafil on cAMP and cGMP levels in isolated human cavernous and cardiac tissue Urology 55 2000 146 150
24. S. ckert, P. Hedlund, and E. Waldkirch Interactions between cGMP- and cAMP-pathways are involved in the regulation of penile smooth muscle tone World J Urol 22 2004 261 266
25. ATP channels reduces contractility of human prostate tissue Prostate 66 2006 377 385
26. P.A. Longhurst, J.A. Briscoe, and D.J. Rosenberg The role of cyclic nucleotides in guinea-pig bladder contractility Br J Pharmacol 121 1997 1665 1672
27. J.I. Gillespie Phosphodiesterase-linked inhibition of non-micturition activity in the isolated bladder BJU Int 93 2004 1325 1332
28. Y. Kaiho, J. Nishiguchi, and D.D. Kwon The effects of a type 4 phosphodiesterase inhibitor and the muscarinic cholinergic antagonist tolterodine tartrate on detrusor overactivity in female rats with bladder outlet obstruction BJU Int 101 2008 615 620
29. S. Oger, D. Behr-Roussel, and D. Gorny Relaxation of phasic contractile activity of human detrusor strips by cyclic nucleotide phosphodiesterase type 4 inhibition Eur Urol 251 2007 772 781